{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,9]],"date-time":"2026-02-09T12:16:22Z","timestamp":1770639382259,"version":"3.49.0"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2005,1,1]],"date-time":"2005-01-01T00:00:00Z","timestamp":1104537600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2015,1,8]],"date-time":"2015-01-08T00:00:00Z","timestamp":1420675200000},"content-version":"vor","delay-in-days":3659,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2005]]},"DOI":"10.1111\/j.1469-0691.2005.01141.x","type":"journal-article","created":{"date-parts":[[2005,4,5]],"date-time":"2005-04-05T06:32:45Z","timestamp":1112682765000},"page":"36-42","source":"Crossref","is-referenced-by-count":75,"special_numbering":"S3","title":["The need for new therapeutic agents: what is in the pipeline?"],"prefix":"10.1016","volume":"11","author":[{"given":"P.M.","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"suppl 3","key":"10.1111\/j.1469-0691.2005.01141.x_bib1","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1111\/j.1469-0691.2005.01138.x","article-title":"Current and emerging serious Gram-positive infections","volume":"11","author":"Menichetti","year":"2005","journal-title":"Clin Microbiol Infect"},{"issue":"suppl 3","key":"10.1111\/j.1469-0691.2005.01141.x_bib2","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1469-0691.2005.01139.x","article-title":"Efficacy of current agents and consequences of resistance","volume":"11","author":"Segreti","year":"2005","journal-title":"Clin Microbiol Infect"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib3","doi-asserted-by":"crossref","first-page":"425","DOI":"10.2165\/00003495-200262030-00002","article-title":"Treatment options for vancomycin-resistant enterococcal infections","volume":"62","author":"Linden","year":"2002","journal-title":"Drugs"},{"issue":"suppl T1","key":"10.1111\/j.1469-0691.2005.01141.x_bib4","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1093\/jac\/48.suppl_2.9","article-title":"Overcoming antimicrobial resistance: profile of a new ketolide antibacterial, telithromycin","volume":"48","author":"Leclercq","year":"2001","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib5","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1093\/jac\/dkf246","article-title":"Linezolid-resistant enterococci: report of the first isolates in the United Kingdom","volume":"50","author":"Auckland","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib6","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.3201\/eid0812.020139","article-title":"Clinical failures of linezolid and implications for the clinical microbiology laboratory","volume":"8","author":"Potoski","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib7","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/S0140-6736(01)05410-1","article-title":"Linezolid resistance in a clinical isolate of Staphylococcus aureus","volume":"358","author":"Tsiodras","year":"2001","journal-title":"Lancet"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib8","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1093\/jac\/dkg104","article-title":"Linezolid resistance in clinical isolates of Staphylococcus aureus","volume":"51","author":"Wilson","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib9","series-title":"Abstracts of the 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"213","article-title":"In vitro activity of iclaprim (AR-100) against Gram-positive and Gram-negative bacteria [abstract E-2006]","author":"Milatovic","year":"2003"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib10","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1056\/NEJMoa025025","article-title":"Infection with vancomycin-resistant Staphylococcus aureus containing the vanA resistance gene","volume":"348","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib11","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1093\/jac\/dkg457","article-title":"Antibacterial susceptibility of a vancomycin-resistant Staphylococcus aureus strain isolated at the Hershey medical center","volume":"52","author":"Bozdogan","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib12","first-page":"322","article-title":"Brief report: vancomycin-resistant Staphylococcus aureus \u2013 New York, 2004","volume":"53","author":"CDC","year":"2004","journal-title":"MMWR"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib13","series-title":"Performance Standards for Antimicrobial Susceptibility Testing; Twelfth Information Supplement","author":"National Committee for Clinical Laboratory Standards (NCCLS)","year":"2002"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib14","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1128\/AAC.47.8.2538-2544.2003","article-title":"Correlation of daptomycin bactericidal activity and membrane depolarisation in Staphylococcus aureus","volume":"47","author":"Silverman","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib15","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1128\/AAC.44.7.1925-1929.2000","article-title":"In vitro activities of daptomycin, arbekacin, vancomycin, and gentamicin alone and\/or in combination against glycopeptide intermediate-resistant Staphylococcus aureus in an infection model","volume":"44","author":"Akins","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib16","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1093\/jac\/dkh104","article-title":"Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci","volume":"53","author":"Rand","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib17","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1128\/AAC.33.8.1198","article-title":"In vitro postantibiotic effect of daptomycin (LY146032) against Enterococcus faecalis and methicillin-susceptible and methicillin-resistant Staphylococcus aureus strains","volume":"33","author":"Bush","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib18","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1128\/AAC.35.9.1710","article-title":"Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs","volume":"35","author":"Hanberger","year":"1991","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib19","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1128\/AAC.45.6.1799-1802.2001","article-title":"Resistance studies with daptomycin","volume":"45","author":"Silverman","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib20","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1128\/AAC.36.2.318","article-title":"Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers","volume":"36","author":"Woodworth","year":"1992","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1128\/AAC.48.1.63-68.2004","article-title":"In vivo pharmacodynamic activity of daptomycin","volume":"48","author":"Safdar","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib22","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1177\/0091270004266619","article-title":"Moderate liver impairment has no influence on daptomycin pharmacokinetics","volume":"44","author":"Dvorchik","year":"2004","journal-title":"J Clin Pharmacol"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib23","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1086\/420818","article-title":"The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections","volume":"38","author":"Arbeit","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib24","series-title":"Abstracts of the 42nd Interscience Conference on Antimicrobial Agents and Chemotherapy","first-page":"180","article-title":"Fluorinated riburamycins as potent MraY inhibitors: synthesis and in vitro biological evaluation [abstract F-359]","author":"Dini","year":"2002"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib25","doi-asserted-by":"crossref","first-page":"1982","DOI":"10.1128\/AAC.43.8.1982","article-title":"Inhibitors of DNA polymerase III as novel antimicrobial agents against Gram-positive eubacteria","volume":"43","author":"Tarantino","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib26","doi-asserted-by":"crossref","first-page":"3750","DOI":"10.1128\/AAC.47.12.3750-3759.2003","article-title":"In vitro and in vivo antibacterial activities of DK-507K, a novel fluoroquinolone","volume":"47","author":"Otani","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib27","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1128\/AAC.44.4.1062-1066.2000","article-title":"In vitro activities of daptomycin, vancomycin, linezolid, and quinupristin-dalfopristin against staphylococci and enterococci, including vancomycin-intermediate and -resistant strains","volume":"44","author":"Rybak","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib28","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1128\/AAC.47.4.1318-1323.2003","article-title":"Daptomycin pharmacokinetics and safety following administration of escalating doses once daily to healthy subjects","volume":"47","author":"Dvorchik","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2005.01141.x_bib29","doi-asserted-by":"crossref","first-page":"4665","DOI":"10.1128\/AAC.48.12.4665-4672.2004","article-title":"Impact of high-inoculum Staphylococcus aureus on the activities of nafcillin, vancomycin, linezolid, and daptomycin, alone and in combination with gentamicin in an in vitro pharmacodynamic model","volume":"48","author":"LaPlante","year":"2004","journal-title":"Antimicrob Agents Chemother"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15600192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X15600192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,2,9]],"date-time":"2019-02-09T16:35:56Z","timestamp":1549730156000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X15600192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005]]},"references-count":29,"alternative-id":["S1198743X15600192"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2005.01141.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2005]]}}}